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Objectives  
           The main objectives of this study were to find out the changes that have 
taken place in the Finnish pharmaceutical market over the last 10-15 years, the 
main marketing techniques and channels used for medicines in the Finnish 
market and – ultimately – to explore if these changes have made the 
pharmaceutical companies to change their current marketing techniques or 
adopt new ones.  
 
Summary  
         The pharmaceutical industry is going through radical changes in the 21st 
century. Among these changes are the decline in the amount of new drug 
development, the generic drugs entering the market, changing regulatory 
environment and the emerging new markets for drugs. In this thesis, qualitative 
interviews were conducted with pharmaceutical companies and a pharmacist 
to meet the objectives stated above.  
 
Conclusions         
            The research showed that in the Finnish market the changes which 
have had the most impact on pharmaceutical companies are the increasing 
industry regulation, the generic entrance and the digitalization of the marketing 
channels.  Due to these changes, companies increasingly put emphasis on 
maintaining relationships to practitioners and internet and social media in 
marketing.  
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1. INTRODUCTION  
 
Staying healthy is one of the grounding needs of all living things. This makes 
pharmaceutical industry one that is fairly sure to remain profitable since people are 
always willing to spend money on their health. This is also a reason that makes various 
stakeholders – society, pharmaceutical companies, doctors, pharmacists, customers 
– interested in the industry. Changes facing the industry regard several entities 
economically but also affect social welfare and people’s general wellbeing.  
As the industry is about making profit with people’s wellbeing, the marketing of 
pharmaceutical products can be ethically questionable. The changes facing the 
industry might complicate the profit-making of pharmaceutical companies: thus, it is 
important to investigate whether they change their marketing and sales strategies and 
the impact they have on the customers. This study examines the changes that have 
taken place in the pharmaceutical industry within the last 10-15 years and how they 
have affected the marketing strategies of the pharmaceutical companies operating in 
the Finnish market. Next the background of the topic will be introduced more 
thoroughly, followed by introduction to the research problem, questions and objectives 
behind this study.   
 
1.1. Background 
 
The pharmaceutical industry is a unique field of business for three reasons. Firstly, it 
deals with people’s well-being. This relates social aspects to it. This leads to the 
second unique issue about the industry which is the exceptional regulation that 
surrounds its business environment (Pharma Industry Finland Code of Ethics, 2017, 
Blumenthal, 2004). Finally, the consumer preferences are not formed by taste but 
consumers’ physical needs. This makes the industry especially research intensive as 
the companies ought to constantly come up with new innovations in order to keep up 
with the competition (Wagner & Wakeman, 2016).  Ultimately the nature of the industry 
is summed up in the notion that the consumer is not capable of assessing the products 
sold by the pharmaceutical companies. This puts them in a unique position in the sense 
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that they are dependent on the information which they receive from the pharmaceutical 
companies, doctors and pharmacists.  
The research intensity of the pharmaceutical industry leads to it being highly patent-
oriented. The patents filed for drugs usually last for 20 years (Budish, Roin & Williams, 
n.d). This means that the patents which have been filed for the traditional blockbuster 
medicines in the past are starting to expire in the course of the 21st century. This is 
only the tip of the ice berg in a discussion of the many changes that have taken place 
and are taking place within the industry during this decade. What derives from this are 
the generic drugs’ market entry and the declining amount of new innovations as there 
is only a limited amount of new raw materials for medicines and they have mostly been 
discovered.  
Finally, pharmaceutical marketing is a highly debated matter since there lies an ethical 
dilemma. In Finland, The Pharmaceutical Industry Finland Code of Ethics sets the 
limits for pharmaceutical marketing. The ground rule is that it is not allowed to market 
prescription medicines directly to the consumers (Pharmaceutical Industry Finland, 
2017). Yet the marketing of prescription medicines to prescribing entities poses a 
conflict of interest as the doctors’ primary concern is the patients’ health while the 
pharmaceutical companies strive to sell their product in order to make profit (Lukkari & 
Parvinen, 2008; Blumenthal, 2004). 
 
1.2. Research Problem 
 
The pharmaceutical industry is going through radical changes in the 21st century. The 
need for new antibiotics is rapidly increasing, patents for old blockbuster medicines are 
expiring and generic versions are entering the market. At the same time the industry 
environment is increasingly regulated. Research is required to assess the impact on 
the sales and marketing techniques of pharmaceutical companies which expect a 
return for the large sums they use in marketing their products to doctors, pharmacists 
and customers. 
 
 
3 
 
1.3. Research Questions 
 
The research questions underlying this study are the following:  
1.  What changes have been seen in the Finnish market over the last 10-15 years? 
2.  What are the main marketing channels and techniques for medicines used by 
pharmaceutical companies in the Finnish market? 
3. Have the pharmaceutical companies changed their marketing practices or 
adopted new ones due to industry changes? 
 
1.4. Research Objectives  
 
Ultimately, this study aims at achieving the following objectives at the end of this thesis.  
1. To find out which of the industry changes that were recognized by the previous 
literature were also recognized by the companies operating in the Finnish 
market. 
2. To determine the main marketing methods for prescription and self-care 
medicines after the industry changes.  
3. To explore if the industry changes have made the pharmaceutical companies in 
the Finnish market to change their marketing practices or adopt new ones. 
Extensive literature can be found on the issue of pharmaceutical marketing. However, 
sufficient research has not been made on the Finnish market. To summarize the first 
chapter, this study aims at contributing to the existing literature in two ways. Firstly, the 
research maps the Finnish market by finding out which of the changes occurring in the 
global market and identified by the literature can be seen in the Finnish market. 
Secondly, the research aims at exploring the marketing strategies of the 
pharmaceutical companies operating in the Finnish market. Not until after this initial 
screening is it possible to meet the above mentioned objectives of this thesis. Next the 
discussion will move on to the existing literature on the subject.  
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2. LITERATURE REVIEW 
 
2.1. Introduction 
 
This literature review aims at developing a conceptual framework for clarifying the 
changes which have occurred within the last 10 years in the pharmaceutical industry 
and their impact on the marketing and sales of pharmaceuticals. The literature review 
will begin by discussing the four key changes that have taken place in the 
pharmaceutical industry over the last decade: decline in discovery, approval and 
marketing of new chemical entities, the generic drugs entering the market, changing 
regulation and the emerging markets. As the industry concerns several different 
entities – consumers, general practitioners, pharmaceutical companies and institutions 
– it is crucial to investigate the existing literature on these entities in order to understand 
the effects of these above mentioned changes. Thus, the literature review will address 
each of these groups before clarifying the current sales and marketing practices used 
by the pharmaceutical companies. These practices vary somewhat between 
prescription and non-prescription medicines which is why they are discussed 
separately in this literature review. Finally, the literature review will conclude by 
presenting a conceptual framework on the impact of industry changes on the sales and 
marketing of pharmaceutical products and different entities in this phenomenon.  
 
This thesis focuses on the Finnish pharmaceutical market. Nonetheless, there are two 
reasons why international sources comprise the bulk of this literature review. Firstly, 
Finland is a part of the European Union (EU) which makes it subject to changes in the 
European market and legislation. Secondly, as it is a relatively small market only a 
limited amount of literature can be found on the Finnish market. In addition, inspecting 
the global trends helps to put the thesis in a wider context.  
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2.2. Changes in the industry 
2.2.1. Decline in discovery, approval and marketing of new chemical entities  
 
New chemical entities (NCEs) can be defined as the compounds emerging from new 
drug discovery (Baines, 2010). In order to maintain economic growth, it is crucial for 
pharmaceutical industry to actively engage in new drug development. It is an industry 
driven by high research and development intensity. (Wagner & Wakeman, 2016). 
Being such an important aspect of the industry, it remains a popular field of study 
among the industry scholars; thus, extensive research and literature can be found on 
pharmaceutical research and development (R&D). Hashimoto and Haneda (2008) 
describe R&D as a stage prior to production, claiming it to be as important as the 
production itself. Becker and Lillemark (2006) describe pharmaceutical industry as a 
technology driven sector, offering a linear model for the industry new product 
development where R&D develops new products and hands them to marketing – 
creating an environment of close collaboration between natural sciences and business.  
Over the last decade, however, the industry has experienced a decline in the amount 
of NCEs (Hashimoto & Haneda, 2008; Mannching, 2015; Gautam, 2016). This results 
in fewer blockbuster medicines making it to the market, potentially causing issues for 
the companies in the industry. Indeed, Baines (2010) states that the value of these 
new launches is significantly less then when the bulk of pharmaceutical companies’ 
revenues were comprised by blockbuster medicines that caused significant increase 
to the revenue. He presents two main reasons for this: the increased scrutiny and 
safety standards from the Food and Drug administrations (FDA) and low success in 
creating new medicines. These reasons will be further discussed in the following 
paragraphs, followed by discussion about the cost of pharmaceutical R&D. As patents 
are an important aspect of new product development in the pharmaceutical industry, 
this section of the literature review will end with discussion on literature concerning 
patents and finally a concluding paragraph with some suggestions on how to address 
these issues drawn from the literature.  
The industry regulation has become stricter both globally and in the Finnish market. In 
Finland, this shows as the reference price system established in 2009, the generic 
substitution launched in 2003 and some changes in the reimbursement system 
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(Lääketeollisuus, 2017). Globally the FDAs’ increased scrutiny and safety standards 
concerning drugs has led to limited approval of NCEs. Nonetheless, Haley & Haley 
(2012) question this notion, stating that is difficult to assess the real impact of 
regulatory burdens on the changes in R&D costs over time. It can be said that the 
impact of regulation on companies’ R&D remains controversial. Yet Haley and Haley 
(2012) present an interesting example from India, an emerging market for the industry, 
that describes the effect of strict regulation on the emerge of NCEs. Under the process-
patent regime, from 1972 to 2004, India grew to be the world’s fourth largest country 
measured by the size of its pharmaceutical industry. Process-patent regime refers to 
regulation where patents are only allowed for the processes of new drug development 
but not the actual products. After 2004, when the country shifted to product-patent 
regime and by consequence from process to product research, there is evidence of 
decreased domestic innovation (Haley & Haley, 2012). This is an example of the type 
of regulation that might be harmful for new drug development. 
Literature shows that R&D efficiency has globally decreased in pharma industry. As 
the process of new drug development is highly costly and demands big investments 
from the pharmaceutical companies, the industry is labelled by great financial risk. It is 
natural for many development projects to result in failure; as this occurs the greater the 
initial investment for R&D, the bigger impact these unsuccessful products have on the 
successful products (DiMasi, Grabowski, Hansen, 2016). This results in firms 
considering their R&D projects with more caution and - ultimately - engaging in less 
new drug discovery. Interestingly, Hashimoto and Haneda (2008) present an example 
of the Japanese pharmaceutical industry where neither diffusion nor innovation of R&D 
technology has occurred over the years 1983-1992. This means R&D efficiency loss 
for the decade; yet firms continuously engage in R&D expenditure. It seems that the 
companies have found another meaning of R&D expenditure beside R&D itself, which 
shows how deeply enrooted R&D is for the industry. Yet Hashimoto and Haneda (2008) 
state that sufficient evaluation of firms’ R&D evaluation has not been made.  
As the industry is highly R&D intensive, the cost of new drug development is an issue 
that is of importance to various entities, especially the drug companies engaging in 
R&D. Studies show that developing new drugs is a relatively expensive process and 
that the research-active – that is, originator companies – spend approximately 17 
percent of the revenues they gain from prescription drugs on R&D (Wagner & 
7 
 
Wakeman, 2016). Indeed, Becker and Lillemark (2006) state that high R&D to sales 
ratio is typical for pharma industry as it is a highly technology driven sector. They also 
note that the expensiveness of industry R&D has led to debates on prescription drug 
prices, importation of drugs, regulatory policies and barriers to entry. The general 
estimation of new drug development seems to be little over $800 million per one NCE 
(Wagner & Wakeman, 2016; Adams & Brantner, 2006). However, Adams & Brantner 
(2006) state $800 million is an underestimation and that there is variation in estimated 
drug costs. Similarly, according to Dimasi, Grabowski and Hansen (2016) the social 
costs of developing new compounds are difficult to measure. Finally, industrial R&D 
also includes a substantial financial risk since many development projects result in 
failure (DiMasi, Grabowski & Hansen, 2016). Therefore, it can be stated that the cost 
of R&D in the pharma industry remains a controversial issue.  
The success of new products emerging from industry R&D is highly dependent on 
patents (Wagner & Wakeman, 2016). Therefore, they should also be examined while 
discussing the industry R&D. Patents can be defined as a period of market exclusivity 
for innovations. In the case of pharmaceutics this is often 20 years. (Budish, Roin & 
Williams, n.d.). Already in the 1780s John Locke has referred to patents as the “fruits 
of labor”, causing controversy whether this means the processes or the products of 
labor (Haley & Haley, 2012). There has also been discussion whether patents provide 
enough protection for the products as companies seem to view secrecy as an even 
more important factor for their products’ success. It has, however, been stated that the 
companies ought to protect their production with patents rather than the end products 
as this kind of “product-patent regime” might reduce innovation (Haley & Haley, 2012). 
This supports the notion of John Locke’s statement referring to the processes of labor. 
  
2.2.2. Market entry of generic drugs   
 
Generic drugs can be defined as the low-cost alternatives for the registered brand 
drugs. Over the last decade generic drugs have entered pharmaceutical market with 
force, causing a substantial drop in medicine prices (Baines, 2010; Mannching, 2015; 
Wagner & Wakeman, 2016; Lukkari & Parvinen, 2008; Lääketeollisuus, 2017). There 
are two reasons for this: the expiring of patents and the economic downturn. Firstly, 
the expiration of the patents of blockbuster medicines enables generic drug makers to 
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undercut the branded products’ profit margin with 6 months. Secondly, together with 
the patent expiration the economic downturn leads to an increase in generic sales and 
dramatic drop in medicine prices (Baines, 2010; Mannching, 2015; Lääketeollisuus, 
2017). The estimation of this increase was from $12 billion to $18 billion between the 
years 2008 and 2012 (Baines, 2010). However, Lukkari & Parvinen (2008) claim that 
this phenomenon is hindered in the Finnish market due to some cognitive institutions 
that make the prescribers maintain their current prescribing patterns, protecting the 
branded drugs (Lukkari & Parvinen, 2008). This can be questioned given the notion 
that a reference price system was introduced in Finland in 2009 to enhance generic 
substition (Lääketeollisuus, 2017). 
 
2.2.3.  Regulatory changes 
 
Regulatory changes have occurred both internationally and in Finland when it comes 
to the pharmaceutical industry (Lääketeollisuus, 2017; Baines, 2010; Gautam, 2016). 
As this thesis focuses on the Finnish pharmaceutical market, mainly the regulatory 
issues relevant to this market will be addressed in this literature review. International 
market will also be touched upon.  
Lukkari and Parvinen (2008) define institutional environment as the “process, 
mechanisms and channels of influence that relate to legitimacy in a particular market”. 
Accordingly, they define regulating as the “evident interaction with regulatory 
institutions that exist to ensure the stability, order and continuity and social welfare”. 
Both of these terms are closely linked to the Finnish drug market which is a typical 
European market; it is defined by tight regulation, strong normative order in terms of 
professions, trade unions and patent associations and, lastly, slowly changing actor 
cognitions. Therefore, for companies operating in Finland the relationships with 
existing institutions are a crucial part of the business and should to be the basis for 
building customer portfolios (Lukkari & Parvinen, 2008).  
Literature shows that the current institutional context of the Finnish drug market is fairly 
dynamic (Lukkari & Parvinen, 2008; Lääketeollisuus, 2017). Over the recent years 
there have occurred various institutional disruptions in Finland. For example, 
establishment of the European Medicines Agency, The European Economic Area 
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agreement have taken place within the last decade, affecting the local business 
network, its wholesale and factory licenses, provision of medical information and its 
marketing authorization processes. This is due to their power of imposing direct 
constraints to the industry. A reference price system was also introduced in 2009 in 
order to enhance generic substitution (Lukkari & Parvinen, 2008; Lääketeollisuus, 
2017). In addition, the membership of the EU causes implications for the Finnish 
regulatory environment. All in all, the regulatory environment in Finland is regarded as 
positive since the professional associations in Finland are considered to be objective 
and educated. Also, new local regulations have been estimated to raise the expertise 
of the local institutional environment (Lukkari & Parvinen, 2008) 
The industry is fairly unstable also internationally when it comes to regulation 
environment. For example, Baines (2010) claims that in the US the economic downturn 
has caused a healthcare debate due to which the pharmaceutical companies need to 
demonstrate the value brought to patients. Similarly, Frank and Newhouse (2008) add 
to this topic by presenting the issue of drug pricing in the U.S. 
 
2.2.4. The emerging markets 
 
In the course of the 20th century the relative importance of the developing world has 
grown for the industry. These “E7” countries are, according to most sources (Baines, 
2010; Haley & Haley 2012; Karpagam et al., 2012), China, India, Brazil, Russia, 
Turkey, Indonesia and Mexico.  All of these countries have the following things in 
common: they are non-industrialized yet have potential for growth (Baines, 2010). 
Three primary reasons for this emergence of new markets can be found from the 
literature as follows. Firstly, historically the US market has been the largest market in 
the industry. However, due to the economic recession the industry has faced years of 
slow growth in the US market and has had to look for new emerging markets for 
production and purchase power. Secondly, these emerging markets have the following 
competitive advantages: their relative costs for R&D and for human resources are low 
and they have a strong demand for new medicines (Haley & Haley, 2012; Gautam, 
2016). Given the industry’s need for new markets, these are substantial advantages. 
Thirdly, less-developed countries have strong product-patent protection in the 
pharmaceutical industry compared to the industrialized countries (Haley and Haley, 
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2012). These factors create a favourable environment for new innovations and market 
entries (Haley & Haley, 2012; Gautam, 2016). On the other hand, Haley and Haley 
(2012) argue that the new regulatory environment that the developing countries have 
adopted hurts domestic innovation. Baines (2010) also presents the challenge this 
development poses for the companies as the diseases, environments and medical 
needs of these emerging markets are not fully understood. It can be stated that more 
research needs to be done to find out the implications of the emergence of the new 
markets for the industry and for the target countries. 
 
2.3. Different entities concerned by the industry 
2.3.1. Consumers  
 
As the pharmaceutical industry ultimately deals with people’s health and well-being, 
the consumers are of critical interest for the pharmaceutical industry, not only for the 
purpose of making profit but to ensure people’s general health (Pharma Industry 
Finland Code of Ethics, 2017, Blumenthal, 2004). Therefore, the customers have a 
special relationship to the pharmaceutical companies compared to other businesses 
since their well-being depends on their products. Yet concerns have been raised about 
the pharmaceutical companies’ unethical practices in marketing and selling which 
corrupts healthcare and – ultimately – risk the consumers’ health (Blumenthal, 2004; 
Cornock, 2015) 
 
2.3.2. General practitioners 
 
The medical practitioners that are most concerned by the industry are those with the 
authority to prescribe or dispense medicines: doctors, dentists, veterinarians and the 
pharmaceutical personnel at pharmacies (Lääketeollisuus, 2017). In Finland the 
profession is highly valued with long traditions - these traditions include cooperation 
between the pharmaceutical companies and physicians’ associations in the 
knowledge-intensive fields of critical research. Indeed, according to Lukkari and 
Parvinen (2008), the Finnish medical association has stated that the professions of a 
doctor and drug industry cannot be separated. This has been argued to result in a 
conflict of interest which will be further discussed in the later sections of this literature 
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review (Lamarche & MacKenzie, 2015; Blumenthal, 2004; Lukkari & Parvinen, 2008; 
Sah & Fugh-Berman, 2013). Ultimately Lukkari & Parvinen (2008) state that the 
legitimacy of the professional associations is a result of the prevalent situation where 
they are in control of the institutional information and considered the leading, objective 
expert organizations. This enables them to strategically influence the industry. 
Conversely, it can be found throughout the literature that the drug companies widely 
influence the doctors (Blumenthal, 2004; Lamarche & MacKenzie, 2015; Sah & Fugh-
Berman, 2013). Thus the literature suggests a two-sided situation where the doctors 
strive to influence the drug industry and vice versa.  
 
2.3.3. Pharmaceutical companies  
 
The literature refers to the world's largest pharmaceutical firms in Europe and the US 
as “The Big Pharma” (Yaqub, 2014; Baines, 2010; Wagner & Wakeman, 2016; Lukkari 
& Parvinen, 2008; Rafols et al., 2014). According to the Pharmaceutical Industry 
Finland, (2017), the biggest pharmaceutical companies in the Finnish market are Orion 
Pharma, Glaxosmithkline, Pfizer, MSD, Roche, Novartis, Takeda, Sanofi, Janssen-
Cilag and Ratiopharm. Rafols et al. (2014) have also in their study listed the “Big 
Pharma” in Europe and in USA. As they also mention Pfizer, Glaxosmithkline, Novartis 
and Sanofi in their investigation, it can be stated that the biggest operators in the field 
are dominant around the world. What is noteworthy is that more similarities can be 
found between the Finnish market and the European market than between the Finnish 
market and the US market.  
 
2.3.4. Regulatory institutions 
 
Medical institutions have, both internationally and in Finland, two important tasks: to 
produce medical information and to regulate the industry (Formoso et al, 2016; 
Lääketeollisuus, 2017; Lukkari & Parvinen, 2008). The critical institutions when it 
comes to the Finnish market are the State as the regulator and professional 
associations as the validating institutions (Lukkari & Parvinen, 2008). Also, the 
European Medicines Agency (EMEA), European Economic Area (EEA) and the EU as 
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they have had a strong influence on the entire medical industry and its practices 
(Lukkari & Parvinen, 2008; Lääketeollisuus, 2017). Furthermore, what is noteworthy 
about the Finnish market according to Lukkari and Parvinen (2008) is that in Finland 
the regulatory institutions have the power to set direct constraints to the companies. 
 
2.4 Marketing and sales in the industry 
 
The current marketing practices of pharmaceutics are very much dictated by the 
Finnish Medicines Agency, Fimea in Finland. It is the authority in charge of controlling 
the marketing of pharmaceuticals (Lääketeollisuus, 2017). More specifically, the 
Pharmaceutical Industry Finland (PIH) Code of Ethics presents detailed provisions on 
pharmaceutical marketing, stating the way it along with pharmaceutical information 
should be targeted at consumers and healthcare professionals in Finland 
(Lääketeollisuus, 2017). As the provisions set for the marketing of prescription-only 
medicine and for the marketing of self-care differ from each other, the following 
paragraphs will consequently discuss the literature written on the marketing of self-
care products and prescription medicines separately. Literature focusing on global 
pharmaceutical marketing practices will also be discussed.   
 
“A pharmaceutical company can inform consumers about various diseases and their 
prevention, diagnosis and treatment. The health information focused on disease 
awareness must guide the consumer towards additional information on health 
promotion and the treatment of the disease” (Pharma Industry Finland Code of Ethics, 
2017).  
 
 
2.4.1 Prescription-only medicines  
 
The PIF Code of Ethics dictates that the marketing of prescription-only medicines in 
Finland can only be targeted at “professionals who are entitled to prescribe or dispense 
medicines and need pharmaceutical information in their work” (Lääketeollisuus, 2017). 
As stated in the paragraphs above, these professionals are doctors, dentists, 
veterinarians and the pharmaceutical personnel at pharmacies. Since prescription-only 
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medicines comprise the bulk of pharmaceutical sales – over 80% - it is an important 
field of business for the pharmaceutical companies (Ebeling, 2011; Lääketeollisuus, 
2017). Thus extensive literature can be found on the techniques they use in marketing 
the prescription-only medicines to the practitioners.  
Pharmaceutical companies’ use of various means of social psychology to influence the 
health care providers has been widely recognized in the literature. These means can 
be divided into financial and non-financial (i.e. deference, opportunity to be revered as 
an expert) inducements (Sah & Fugh-Berman, 2013; Ebeling, 2011). Next both of 
these will be discussed in further detail, followed by discussion on the dilemma of 
“conflict of interest” that is mentioned several times throughout the literature.  
Financial ways that the companies use to influence the physicians prescribing are gifts, 
sponsored research and education grants. This influencing may begin already during 
the education of the doctors and continue throughout their careers (Ebeling, 2011; Sah 
& Fugh-Berman, 2013; Blumenthal, 2004). Indeed, Blumenthal (2004) describes this 
interaction as “pervasive” and states that it influences negatively on the quality of health 
care. The physicians are mostly confident that they can objectively prescribe, yet there 
is evidence of the occurrence of this negative influence (Sah & Fugh-Berman, 2013; 
Blumenthal, 2004; Lamarche & MacKenzie, 2015). Thus, Sah & Fugh-Berman (2013) 
have identified the ways of denial through which the professionals remain unaware of 
the industry’s influence. These are the following: avoiding thinking about the conflict of 
interest, rejecting that the industry relationships affect physician behaviour and 
universalizing the responsibility for problems arising from conflicts.  
Similarly, Sah and Fugh-Berman (2013) have identified the principles of persuasion 
that the companies use to convince the physicians; the first of these, reciprocity, can 
be categorized as one of the financial ways. By this they refer to the obligation to help 
those who have helped you – in which case receiving a gift triggers such a state. This 
is also addressed by Blumenthal (2004) as he states that the size or importance of the 
gift remains insignificant in terms of the formation of a reciprocal relationship. On 
national level these gifts may be industry grants, on an institutional level educational 
grants and on an individual level fees for research or – a gift of value as negligible as 
a pen – to maintain the brand name in the physicians’ minds and trigger reciprocity 
norms.  
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The non-financial ways that the companies use in influencing the practitioners include, 
for example, the possibility of being considered an expert. They can also be inspected 
through the principles of persuasion presented by Sah and Fugh-Berman (2013) They 
include commitment and consistency, social proof, liking and authority. Lukkari & 
Parvinen (2008) address the third principle, liking, by stating that pharmaceutical 
companies intentionally engage in building networks to the prescribing professionals 
in order to maintain favourable customer portfolios. They argue that, ultimately, this 
interaction between the practitioners is merely customer portfolio managing in the 
highly institutionalized drug market and thus requires continuous, intentional 
networking on behalf of the drug companies. Finally, Sah and Fugh-Berman (2013) 
recognize the two principles behind successful building of non-financial commitment to 
the pharmaceutical companies: people tend to believe messages delivered with 
confidence and that people anchor on initial information. The latter is supported by 
Lamarche’s & MacKenzie’s remark (2015) that only 7% of new drug info gained by 
practitioners comes from other sources than pharmaceutical companies. 
It is crucial that the different entities gain correct pharmaceutical information which 
enables the correct use of medicines. It is a precondition for people’s health and 
working capacity and, on the other hand, the best treatment practices (Lääketeollisuus, 
2017; Blumenthal, 2004). Given this notion the conflict of interest deriving from the 
physicians’ interactions with the companies is troublesome. Factors behind this conflict 
of interest reach beyond merely the pharmaceutical companies pursuing sales and the 
physicians working for the benefit of curing diseases; the government spending on 
drugs and the personal interests which professionals may have are also a part of this 
conflict (Lukkari & Parvinen, 2008; Blumenthal, 2004; Lamarche & MacKenzie, 2015). 
The literature presents several reasons for the existence of cognitive dissonance. 
Firstly, Sah and Fugh-Berman (2013) claim that the conflict of interest is due to 
cognitive dissonance, a discomfort that arises from conflicting beliefs and that the 
physicians try to avoid. On the other hand, Lukkari and Parvinen (2008) say that this 
is due to the intentional relationship building which the companies engage in. Both of 
these notions support the existence of subconscious biases that prohibit the doctors 
from being aware of such conflict (Sah and Fugh-Berman, 2013). Other reasons 
presented by Lukkari and Parvinen (2010) are the long traditions of co-operation which 
the pharmaceutical companies and physicians have. What should be noted is the 
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ultimate impact of this situation on the consumer: overuse of expensive branded drugs 
and potentially negatively influences on the quality of health care (Lamarche & 
MacKenzie, 2015; Blumenthal, 2004; Lukkari & Parvinen, 2008; Sah & Fugh-Berman, 
2013). 
 
2.4.2. Self-care medicines 
 
In Finland the PIF Code of Ethics allows only the marketing of self-care medicines 
without prescription to consumers (Pharma Industry Finland Code of Ethichs, 2017). 
Therefore, the issue of direct-to-consumer advertising will be discussed in this section 
concerning non-prescription medicines. Yet what should be noted is that the global 
situation differs from that of the Finnish market in that the FDA has allowed direct-to-
consumer advertising also for prescription pharmaceuticals already in the 1980s in the 
USA (Ebeling, 2011; Mihm, 2013).  Globally the following trends in marketing self-care 
medicine can be discovered from the literature: personal selling and online marketing. 
In the following these will be discussed in the context of the Finnish market as well as 
globally.  
Globally the issue of direct-to-consumer-advertising (DTC) of prescription medicines 
has been a highly debated matter (Mihm, 2013). Indeed, Ebeling presents that DTC is 
used to “brand” illnesses and promote the sales of certain drugs. Though this is not an 
issue in Finland, some controversial aspects can also be found from the advertising of 
non-prescription medicines. For example, Mihm (2013) found that there are gender 
related differences in companies’ direct-to-consumer marketing as women were 
targeted at twice the rate of males in the gender specific ads. He also identifies the two 
primary types of advertising appeals: informational appeals using the uniqueness of a 
product and emotional appeals appealing to consumer’s feelings to match their wants.  
The emergence of online pharmacies has brought up the emergence of online 
pharmaceutical marketing, changing the world of health care by enabling the purchase 
of drugs without consulting a physician (Levaggi et al., 2009). There are differences in 
the marketing strategies of online pharmacies compared to the regular pharmacies. 
Firstly, they are more focused on non-prescription drugs and health foods. Secondly, 
the literature suggests that their marketing and pricing strategies resemble those of a 
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commodity market as they vary according to variety, quality and target group. They 
also use hot sales lists, free delivery and other unusual means for regular pharmacies 
in their marketing (Su et al., 2013; Levaggi et al., 2009). While providing the various 
people with access to medicine round the world, the issues brought by online 
pharmacies have also been addressed. According to Levaggi et al. (2009) selling drugs 
via internet can turn into public health risk since it is an unregulated market and 
encourages the misuse of drugs. Here it should be noted that even if most online 
pharmacies did not require prescriptions, within the EU article 30 justifies a national 
prohibition on the “sale by mail order of medical products subject to prescription” 
(Levaggi et al., 2009). 
Due to the nature of the industry there are certain challenges in the marketing of 
pharmaceuticals. Firstly, there are certain demands for the minimum information that 
should be present in an advertisement of a medicine. In Finland the PIH Code of Ethics 
dictates this (Pharmaceutical Industry Finland Code of Ethics, 2017). Globally this is 
done by the FDA. The challenge of direct-to-consumer ads is that they should provide 
adequate information in a short period of time (Su et al, 2013).  In addition, the R&D 
intensity of the industry brings some challenges for the marketing of medicines (Becker 
& Lillemark, 2006; Wagner & Wakeman, 2016). According to Becker and Lillemark 
(2006) it is a challenge to integrate the traditional marketing role to pharmaceuticals 
since the consumer needs are not influenced by taste - thus discovery is merely 
creating new innovations. Also the speed of product commercialization is slow due to 
obligatory clinical trials (Wagner & Wakeman, 2016). Finally, patents cause issues in 
the marketing of medicines due to the long time lag between commercialization and 
filing patents; as they must be filed at the time of the innovation, the effective time of 
marketing while the patent is still effective often remains short (Wagner & Wakeman, 
2016; Budish, Roin & Williams, n.d). 
 
2.4. Conceptual Framework 
 
It can be concluded from the literature that four major changes have occurred in the 
pharmaceutical industry within the last ten years. This has an impact on the different 
entities on the industry: regulatory institutions, general practitioners, consumers and 
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the pharmaceutical companies conducting pharmaceutical marketing. The situation 
can be portrayed in a conceptual framework shown in Figure 1.  
Figure 1: Conceptual Framework 
Firstly, the four changes – decline of NCEs, market entry of generic drugs, regulatory 
changes and the new emerging markets – have changed the industry environment, 
affecting the different entities in the industry. This can be seen from the large green 
arrow. Also, the relationships between these entities can be seen from the framework. 
The regulatory institutions set regulations, thus exerting their power over the 
pharmaceutical companies. Moreover, the regulations affect the general practitioners 
as they are guidelines for their work. Another important task these institutions have is 
to convey trustworthy medical information to the consumers. A noteworthy relationship 
in this framework is the reciprocal relationship of the pharmaceutical companies and 
the general practitioners as they engage in two-way influencing with each other. 
Ultimately, the consumers are influenced by the general practitioners as they seek 
medical advice and guidance from them. The small green arrow in the framework 
portrays the new output that the companies produce after these industry changes, the 
pharmaceutical marketing. This marketing is directed at both the general practitioners 
and the consumers. 
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3. METHODOLOGY 
 
This section of the thesis describes the methodology used for conducting the research. 
Methodology is the theory of how research is intended to be undertaken in a study – 
thus it is a crucial part to understand the research for both the researcher and the 
reader of the study (Saunders, Lewis and Thornhill, n.d.). It is important in terms of 
understanding why a certain approach has been chosen for the research as well as 
the objectives of the research.  
Next the research approach - the ideology behind researching the chosen topic – will 
be discussed. The research objectives underlying the chosen research approach will 
also be addressed. This will be followed by discussion on the actual data collection 
method. For the sake of clarity, it should be mentioned here that the term “method” is 
used when referring to the techniques used for gathering and analyzing data as 
opposed to the term “methodology” which was defined in the previous paragraph 
(Saunders, Lewis and Thornhill, n.d).  
 
3.1. Research approach 
 
The first decision when developing the research approach for this study was to decide 
whether to use merely secondary data for the research or engage in primary data 
gathering. Gathering secondary data via exploring the written literature is a crucial part 
of every research. Indeed, quoting Lukkari & Parvinen (2008): “Pure induction without 
theoretical reference might prevent researchers from benefiting from previous work.” 
Realizing the importance of the literature survey, the nature of this thesis also called 
for primary data collection since it intends not only to find out how marketing is done 
but also why and what are the underlying phenomena behind this. Moreover, the 
Finnish market is such a small market that sufficient literature from its current marketing 
procedures to conduct entirely secondary research could not be found. Thus I chose 
to first thoroughly engage in literature survey and after that secondary data gathering. 
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Consequently, deciding whether to use quantitative or qualitative data in this research 
followed this decision of data gathering method. From these two, the qualitative basis 
was chosen for the following reasons. Firstly, as this thesis focuses on studying the 
marketing practices of a specific field of business, its theories originate mainly from the 
field of marketing. They are often researched with the means of qualitative methods. 
Qualitative methods refer to methods where images and words are used in explaining 
situations (Carcary, 2009). Moreover, pharmaceutical marketing is a field of marketing 
that should be considered separately from other marketing in business. This is due to 
the strict institutional regulation that dictates the industry policies. This makes its 
environment unique: thus it is more convenient to be measured via qualitative research 
methods as they are flexible and sensitive to the context (Carcary, 2009). 
From the large pool of qualitative data collection methods, interviews were chosen for 
the primary data collection method of this thesis. This is due to the nature of the study 
that is rather an exploratory one - a study intended to find out “what is happening, 
seeking new insights and to assess phenomena in a new light”. That is, it aims at 
establishing causal relationships between variables (Saunders, Lewis and Thornhill, 
n.d). This thesis aims at explaining the relationship between the current 
pharmaceutical marketing strategies and the changes taking place in the industry. As 
Saunders et al. (n.d.) suggest, “interviewing experts in the subjects” is a convenient 
way for conducting an exploratory research. In the context of this thesis it was most 
suitable to choose certain corporate elites – the marketing managers of pharmaceutical 
companies – to be interviewed since they are experts to tell about their company’s 
marketing procedures.   
The benefits of personal interviews over, for example, filling a questionnaire, has been 
widely recognized (Kothari, 2014; Saunders et al, n.d.). The benefits that contributed 
to the choice of personal interviews for this thesis are the following. Firstly, this allows 
the interviewer to have complete control over who answers the questions (Saunders 
et al, n.d.). Secondly, personal interviews enable the collection of more information that 
is of greater depth. Thirdly, it enables spontaneous reactions as opposed to mailed 
questionnaire (Kothari, 2014).  Moreover, it has been found that managers prefer being 
personally interviewed over filling a survey. In addition to the convenience of personal 
interview, in person it is easier for them to receive personal assurance about the 
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confidentiality of the information (Saunders et al, n.d.). This latter point is essential in 
the context of the pharmaceutical industry as it is very strictly regulated.  
More specifically, semi-structured interview was chosen for this research. A structured 
interview involves “the use of a set of predetermined questions and of highly 
standardized techniques of recording” (Kothari, 2014). Though a sort of structure was 
needed for the interviews to reassure the gathering of relevant information, this specific 
structuring did not suit the purpose of this thesis for two reasons. Firstly, using strictly 
predetermined questions would have hindered the interviewees from engaging in free 
discussion on the topic. To gain an in-depth understanding on the field it was crucial 
that the interviewees could add points that they considered worth mentioning. In 
addition, “highly standardized techniques of recording” could not be used for this 
research. Thus, semi-structured interview was chosen for the research approach of 
this study.  
 
3.2. Data collection 
 
The sole primary data collection method for this thesis was interviews. The data was 
drawn from five interviews in total: one pharmacist, two marketing managers in charge 
of self-care medicine and two marketing managers in charge of prescription-only 
medicine. The interviewees were chosen using the following criteria. 
Firstly, within the time limits set for this thesis any number of interviews was deemed 
to be small; a better outcome could be achieved by concentrating on either the 
conducting or the receiving end of the marketing. In this thesis, the conducting party 
was chosen. Hence the aim was to interview the entities conducting pharmaceutical 
marketing – the pharmaceutical companies. As this thesis focuses on the Finnish 
market, the primary criteria for choosing the companies was that they were reasonably 
big companies and operated in the Finnish market. This is to ensure the gathering of 
relevant data from the Finnish market. An important notion here is that the strict 
industry regulation sets very different criteria for the marketing of self-care medicines 
as opposed to the prescription medicine. To gain full understanding of the 
pharmaceutical marketing it was important to interview experts of both fields. 
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Therefore, both marketing managers of self-care and prescription medicines were 
contacted. 
Secondly, while concentrating on the companies’ perspective, to gain a full 
understanding of the industry an interview from the target of the marketing was also in 
order. As stated in the literature review, the options for this were doctors and 
pharmacists. Even though a doctor was also considered to be interviewed for this 
thesis, it soon became clear that in Finland many private chains regulate the 
pharmaceutical marketing to doctors. Thus, within the time restrictions it was easier to 
find a pharmacist to interview. A pharmacist in charge of a pharmacy that is a member 
of a big pharmaceutical chain in Finland was chosen to be interviewed. Table 1 
summarizes information on the contacted companies and the interviewees.  
 
Table 1: Interviewees 
Interviewee Company Core operations 
Operating 
area 
Headquarters 
Marketing director 
of prescription 
medicines 
Company 
A 
Drug research and 
development. 
Undisclose
d 
Undisclosed 
Marketing director 
of self-care 
products 
Marketing director 
of prescription 
medicines 
Company 
B 
Drug development and 
testing for people and 
animals. 
100 
countries 
In Espoo, 
Finland 
Marketing director 
of self-care 
medicines 
Pharmacist Company 
C 
Selling medicines and 
self-care products 
- - 
 
The data collection phase included the following steps. It began with contacting the 
chosen companies. All the interviewees were approached the same way: they were 
first sent an email followed by a phone call to ensure the response and reaching the 
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right person. However, as company B did not have the contact information of its 
marketing management on its Facebook site, the contacting process proceeded 
slightly differently as it happened via the company’s communications manager. Also, 
the pharmacist was contacted merely via phone call. After getting responses from all 
the interviewees a date and time for the personal interview was set. All the interviews 
were conducted in person, using a mobile device for the recording. The aim was to 
create a most natural, relaxed environment for the interview to ensure that the 
interviewees could pursue also topics other than those set by the initial structure of the 
interview. To ensure this it was mentioned in the beginning of the interview.  
Due to the industry’s regulated nature the pharmaceutical companies demanded to 
see the questions beforehand. This had to be taken into consideration in the data 
analysis part of this thesis as that was not the case with the interview with the 
pharmacist. Yet this thesis aims at drawing a thorough image of the industry’s 
marketing procedures based on the interviews. In the light of this notion the ability to 
directly compare is not as relevant as the ability to draw new insights from the 
interviews. Thus, it can be said that the data is equally usable.  
The limitations of this research can be summed up in four bullet points as follows: 
 Limited time for data collection 
 Relatively small total number of interviews 
 Lack of an interview with a prescribing doctor due to the time limit 
 Some interviewees seeing the questions beforehand 
 
 
3.3. Data analysis 
 
The data analysis part of this thesis consisted of two main phases. First the interviews 
were listened to and transcribed. Next the main points were found from each interview. 
This was done as the basis of the findings chapter. After this, the main points were 
grouped to find differences and similarities among the interviews. Finally, these 
differences and similarities were analyzed using the literature review as well as the 
conceptual framework of this thesis to conduct the chapter on analysis. This analysis 
was used to form the final conclusions of this thesis.  
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4. FINDINGS  
 
In this section the main findings from the primary research of this thesis – 5 interviews 
with four from the industry aspect and one from a pharmacist – will be discussed. The 
findings are organized utilizing the features of the conceptual framework as sub-topics. 
These consist of two bigger concepts: the changes in the industry and the current 
marketing practices of medicines. The empirical material is summarized accompanied 
by direct quotations from the interviews; this ensures the capturing of the original 
message of the interviewee.   
 
4.1. Changes in the industry 
 
What could be drawn from the interviews is that major changes have taken place in 
the industry within the last 10 years which have had an impact on the entities operating 
in the Finnish market. These changes will be discussed in the next paragraphs, 
following the themes which occurred in the literature review.  
There are certain issues that should be noted with regard to the findings related to the 
industry changes. Firstly, ten years is a long time; some of the interviewees had not 
been within the company long enough to be able to assess some of the changes which 
occurred within these years. Secondly, the interviewees from the drug companies were 
responsible for the marketing of their companies’ products. Therefore, certain topics 
inevitably fell out of their responsibility areas which meant that they could not respond 
thoroughly to some of the questions.    
 
4.1.1. Decline in discovery, approval and marketing of new chemical entities 
 
When it comes to the discovery of new chemical entities (NCEs), what stood out from 
the interviews is that both the medical companies seemed to hold creating new 
innovations in great value. All their interviewees stated that creating new innovations 
is the core of their business. More specifically, innovating new medicines seemed to 
be their primary concern.  
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The common ground among the interviewees was also that they did not seem to notice 
any decline in the amount of new product discovery. Indeed, according to the 
pharmacist, new products came in every week. In addition, interviewees from company 
A stated that in the recent years the amount of new product launches has rather been 
in an increase. The common opinion was that if there was any decline it was due to 
mere seasonal changes.  
What is noteworthy here is that the interviewees seemed to have considered the whole 
product range – the prescription- and self-care medicines as well as self-care products 
when answering this question of the recent trends in new medicine launches. The 
situation is different when considering only the NCEs since discovering completely new 
medicines is rare. Indeed, a quote from an interviewee from Company B summarizes 
the situation:  
“Recent years have been good in terms of product launches – we have had approximately 
ten new product launches within the last five years. Though now that I think about the 
question, approximately 30% of these launces have been medicines, only 1-3 new medicines 
in five years, that is…” 
In addition, the Finnish market is strictly regulated due to which it is rather complex to 
launch a new medicine. Both companies A and B noted that the product launches are 
entirely dependent on which medicines are granted the sales permission. The 
interviewee from the self-care medicine side in company B described the situation as 
follows:  
“I think the trend is that the amount [of NCEs] is decreasing... And it’s the same thing for the 
prescription-medicines; the ones that have gone generic have gone generic and the next 
round is coming in 2000-something when certain medicines begin to go generic. Be that as it 
may, there are not many medicines left that have patents.” 
 
4.1.2. Market entry of generic drugs  
 
All the interviewees recognized the impact that the generic drugs’ market entry has 
had on their pricing. However, they seemed to consider this development as a natural 
consequence from the strict market regulation. All the interviewees from the drug 
companies agreed that the generic drug entrance has not changed their pricing 
strategies but that there is rather a causal connection between the generic drug 
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entrance and the overall decline in prices. As described by an interviewee from 
Company B: 
“A product comes in that has not had the research and development cost and all the 
products’ prices go down. That’s part of the business.” 
Also, the common opinion of the drug companies was that they do not focus on 
producing the generics but that their focus is on delivering new innovations. They also 
highlighted that once their own product’s patent expires they strive to make their own 
alternative for this product in the generic side. Here the contrast should be noted 
between the statements of the drug companies’ representatives and the statements of 
the pharmacist; whereas the drug companies highlighted their focus on the original 
innovations, according to the pharmacist these companies do make “copies” of other 
companies’ medicines also.  
What is most noteworthy about the interviews is that neither of the drug companies 
considered the generic entrance as a threat to their core business – the original 
innovations.  Interviewee from company B even stated that competition is always good. 
What arose from the interviews is that the market is fairly saturated in Finland in the 
sense there is a vast number of products in all product categories. An interviewee from 
Company B recognized this by stating that it is challenging for a new company to enter 
the market in the current circumstances. A quote from the pharmacist clarifies the 
situation from the pharmacists’ end:  
“We have pretty much stuck to these companies as there is no reason to take more from 
another company; there is limited amount of space and if we take something from a company 
it demands its own storage space.” 
As the interviewed drug companies are big operators in the Finnish market with long 
traditions, they do not have a reason to regard the generic entrance as a threat to their 
business.  
 
4.1.3. Regulatory changes  
 
All the interviewees recognized the highly regulated environment of the industry. The 
following quote from the pharmacist describes the situation well:  
“You always come across regulation when you mention the word drug.” 
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However, both the pharmacist and an interviewee from company B’s prescription side 
recognized that this is due to the fact that consumer is not qualified for assessing 
prescription medicine and thus regulation is in order. Therefore, they regarded 
regulation as a positive thing.  
The biggest regulatory change that the companies recognized was the reference price 
system. An interviewee from Company A even described the impact of the reference 
price system on their business as “dramatic”. This is mainly in the prescription side. 
According to the interviewee from Company B there are fewer and fewer branded 
products as they become interchangeable.  
In contrast, the interviewed drug companies did not seem to recall that the membership 
of EU has had a big impact on their business. Both the drug companies did recognize 
the impact of the EU harmonizing the legislation of its member countries; however, 
from the Finnish perspective they did not think this has had a big impact on the market 
environment. An interviewee from Company B recognized the impact of the EU with 
two main points. Firstly, the free movement of products that brings with it international 
competition. Secondly, the centralized marketing authorization from EU. The main 
impact of the EU is that nowadays when a new product is launched, a centralized 
marketing authorization is pursued that comprises the entire EU area. He too, however, 
regarded the impact of these two as fairly small. From the self-care medicine side of 
Company B the interviewee stated that it becomes costly when the EU unifies the 
legislation of the member countries as this requires changes in, for example, 
packaging.  
Overall, the interviewees thought that over the last 10 years the regulation has become 
stricter and The Finnish Pharmaceutical Industry Code of Ethics has become even 
more specific.  
 
4.1.4. The emerging markets  
 
When asked about the manufacturing locations of their products, all the interviewees 
from drug companies were rather hesitant in answering. The interviewees from 
Company A named Europe and the USA as some of their manufacturing locations but 
could not specify the locations due to the large amount of their manufacturing facilities 
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around the world. As the reason for the multiple production locations they said that a 
back-up alternative is needed in case there occurs problems in the production or supply 
chain in one country. Company B, however, highlighted their domestic production as 
they have manufacturing facilities also in Finland. The interviewee also added that the 
company does have some production abroad but that the Company does not further 
discuss the location of this production.  
Furthermore, the interviewees from the drug companies were unable to specify 
whether there has occurred any trends in new manufacturing facilities.  
“I cannot answer this since we are only told where the products come from. Though I don’t 
think any major changes have occurred.” 
The pharmacist noted that drug companies actively follow the global situation of the 
manufacturing locations. In addition, according to the pharmacist, domestic production 
in Finland is these days so small that it is nearly non-existent. She also mentioned the 
trend of centralizing production to certain countries that, for example, have the needed 
raw ingredients – such as India.  
 
4.2. Marketing and sales in the industry  
 
The main theme that was present in all the statements about pharmaceutical marketing 
was the strict regulation. The ground rule is that The Pharmaceutical Industry Finland 
Code of Ethics sets the criteria for pharmaceutical marketing which is monitored by the 
Supervisory Commission for the Marketing of Medicinal Products. This regulation sets 
very different criteria for the marketing of self-care medicines and the prescription 
medicines. Thus, the findings concerning each of these will also be discussed 
separately, starting with the prescription medicines and then moving on to the findings 
about the marketing of self-care medicines.  
When it comes to the importance of prescription and self-care medicines, somewhat 
differing statements were made by the pharmaceutical companies. On one hand, 
company B stated that both are financially equally important. On the other hand - as 
creating new innovations for curing diseases was named as the primary importance 
for both companies -  the prescription medicines were named important prescription-
wise. The companies were also somewhat reluctant in stating which takes more of their 
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marketing budget; it was merely revealed that traditional medias are costly marketing 
channels and they are only used for the marketing of self-care medicines.  
 
4.2.1. Prescription-only medicines  
 
Prescription medicines cannot be marketed to the consumer under any circumstances. 
This forms the foundation for the marketing of prescription medicines which was also 
apparent in the interviews. When asked about the main marketing channels for 
prescription medicines, all the interviewees mentioned this as the most important issue 
when choosing the marketing channels for prescription medicines; they must be 
chosen carefully so that they cannot reach the consumer even by accident.  
With this primary condition in mind, various marketing channels were mentioned by the 
interviewees. All the interviewees mentioned professional training provided by the 
pharmaceutical companies as an important part of the companies’ marketing mix. 
Another main channel that was mentioned was the use of representatives. Company 
B’s representative highlighted that when it comes to prescription medicines,”face to 
face” operations are the biggest part of the companies’ marketing mix. What should be 
noted is the difference to the self-care medicines. According to the interviewee from 
Company B, traditional media such as radio and TV play an insignificant role in the 
marketing mix of the prescription medicines.  
Besides this, different channels targeted at professionals were mentioned such as 
intranets, professional magazines and websites. The pharmacist described the 
information that is targeted to the pharmacies as follows:  
“All channels are in use – one could read information about new medicines from sun up to 
sun down.” 
In the following sections these channels will be further discussed. The discussion will 
proceed in accordance with the themes seen in the literature review: first the non-
financial ways will be addressed and after that the financial ways.  
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4.2.1.1. Non-financial ways 
 
The non-financial strategies of marketing prescription medicines aim at building and 
maintaining relationships with pharmacists and prescribing doctors. The empirical 
findings show that the non-financial ways of marketing are of high importance when it 
comes to the prescription medicines. As stated by the interviewee from Company B:  
“This is ultimately about sales… A medicine is no better than any other product in the sense 
that it could sell itself; it is up to the marketing and sales functions to do that.” 
In terms of the non-financial ways of marketing medicines, the main means for this are 
the representatives. Indeed, the findings from the interviews show that representatives 
are broadly at use in the industry. They are sent to visit pharmacists and prescribing 
doctors on a regular basis to give information about the company’s products. Both 
pharmaceutical companies stated that these representatives have geographical 
responsibility areas but also areas of specialization; according to the interviewee from 
company B, one group is sent to visit doctors and another to visit pharmacists. 
According to the pharmacist, different pharmaceutical companies send representatives 
to visit the pharmacy weekly. Furthermore, they might hold regional information 
sessions or education seminars.  
Interestingly the pharmaceutical companies’ statements about the aim of the use of 
representatives slightly differ. The interviewee from Company A highlighted that their 
purpose is merely informative;  
”When new drugs are launched it is important is to make sure that the doctors know how to 
use them. The most important task of the representatives is to talk about this and the 
benefits the product has for the patient” 
The interviews with Company B, however, stressed on the representatives’ 
responsibility in selling the product:  
“The representatives meet plenty of doctors and try to argue for their own product – though it 
is very limited what can be said [about the product]. It is sales job; you’re trying to make an 
impression so that your drug would be prescribed.” 
Interestingly the pharmacist noted that it is both ecologically and economically 
inefficient for the companies to physically send out representatives to talk about their 
products. Yet they are still widely used as the most important tool for marketing 
prescription medicines. The reason for this can be drawn from the empirical data – the 
value of the representatives does not seem to lie so much in the information they 
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provide but the personal relationships they build.  All the interviewees declared that the 
goal is to have the same representatives regularly visit the same doctors and 
pharmacists. As the reason for this the pharmacist stated that it is nice to have “a 
familiar face” to the company. Company A’s interviewee said that the reason for this is 
that it facilitates things to have the same person visit the same people.  
The drawback of this personal relationship with the representatives also emerged in 
the interviews. The pharmacists and the doctors have the power of determining which 
representatives they meet – or refuse to meet. A quote from the pharmacist clarifies 
the situation:  
”The pharmacists decide who is accepted to present [their product]; some are not accepted if 
they are annoyed with them or do not want to use the personnel’s time” 
In addition, all the interviewees stated that the information about new medicines comes 
primarily from the representatives. The doctors have the authority to prescribe 
medicines and the pharmacists have the authority to recommend alternative general 
products for the prescriptions. Thus, it is a preliminary condition for different drugs to 
be prescribed that the representatives are allowed by the doctors and pharmacists to 
present them.  
Besides using the representatives, another important way of maintaining relationships 
with the practitioners is the collaboration that drug companies do with the practitioners. 
Both the drug companies stated to have collaboration contracts with all the large 
pharmaceutical chains in Finland. When asked to describe their co-operation with 
pharmacists and doctors, one could again note the difference in weighting between 
Company A and Company B’s statements. Company A – once again – highlighted that 
they have many types of co-operation but mainly educational. Company B stated that 
it is mainly marketing collaboration. Company A, however, seemed to consider the 
quality of education as the primary concern in terms of maintaining relationships with 
the practitioners:  
“The quality image of the practitioners is formed via the quality of the education; that is what 
the doctors appreciate these days and that is what the relationship to the representative and 
the whole company is dependent on. That we have relevant speakers and that the education 
is related to the products but also benefits the doctor and the patient.” 
Finally, the importance of the representatives again came up in this context. The 
pharmacist stated that the companies that they have most in common with are the 
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ones who market both prescription- and self-care medicines as they are visible more 
often in the everyday lives of the pharmacies.  
 
4.2.1.2. Financial ways 
 
The financial ways of marketing prescription medicines to doctors and pharmacists 
refer to anything with monetary value that the drug companies might hand out along 
with their product information. The change in industry regulation within the last century 
was apparent in the interviews – all the interviewees stated that the PIF Code of Ethics 
regulates strictly the handing of any types of gifts to the practitioners in Finland. Thus, 
companies focus on providing education when it comes to the financial ways of 
marketing their products.  
The interviewees highlighted that the representatives are only allowed to have 
educational material with them as they visit the doctors and pharmacists. All the 
material that they can hand out is dictated in the PIF Code of Ethics. This means mostly 
different educational handouts. As stated by the interviewee from Company B, usually 
the representative’s visit occurs during café or lunchbreaks when it is normal to bring 
some café or bakery products but nothing more. Company A also addressed the issue 
well:  
“The industry change is apparent in the Code of Ethics; these days it is not allowed to leave 
so much as a pen but merely educational material” 
The interviewee also continued on the subject, saying that this development is “a few 
years old”. In the past it was allowed for medical companies to leave gifts related to 
the doctor’s profession – the shift to the current state has occurred incrementally.  
Despite this it is still usual that the companies provide training for the practitioners. This 
training means organizing education seminars for pharmacists both live and virtually. 
The virtual educational possibilities were brought up several times over by the 
pharmacist as a “new revolutionizing form of education”. In addition, there are different 
fairs for all the healthcare professionals where pharmaceutical companies can be 
present. Both companies seemed to recognize the importance of providing quality 
education. Interviewee from Company B stated the following on the matter:  
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“The only way to get people to attend these trainings these days to ensure that the program 
is good and that it is experienced as neutral but that the company also has its own turn to 
speak.” 
The interviewee from Company B also commented on the shifting nature of the 
provided training: 
“These days it is naïve to think… people make their own decisions and that you would have 
some completely commercialized event; a miracle doctor coming to tell you about a 
treatment and suddenly everyone decides to use it… that does not really happen.” 
Yet it was also apparent in the interviews that education provided by the 
pharmaceutical companies is often considered as biased by the public entities.  
Finally, sponsorships are used as financial ways of marketing the prescription 
medicines. When it comes to sponsoring, both medical companies stated that they do 
not directly sponsor any events; only in the form of charity donations. 
4.2.2. Self-care medicines  
 
Differing from prescription-medicines, self-care medicines can be directly marketed to 
the consumer in Finland. Nevertheless, the interviews showed that the marketing is 
strictly regulated by the PIF. Firstly, discounts cannot be provided on any medicines. 
Thus, there are no medicines present on, for example pharmaceutical chains’ monthly 
discount magazines. Secondly, as stated by the interviewee from Company B, there 
must be certain information present when marketing medicines to consumer:  
“If you follow for example radio advertising, the reason why they always say the same 
standard things – read the package description carefully, not suitable for children and such – 
it is because it must be present when it comes to medicines since the law states that.” 
When asked to name the primary channels for self-care medicines, both traditional 
media and digital marketing were mentioned. Most importantly, Company A named 
pharmacies as the most important channel for marketing their products. Specifically, 
two ways in which the pharmacies can market the medicines came up in the interviews. 
Firstly, campaigns realized in co-operation with pharmacies were brought up by both 
pharmaceutical companies. The fulfillment of the campaigns as well as their success 
is carefully monitored by the companies via sales and representatives. Furthermore, 
the pharmacists are well educated about the medicines and can recommend them to 
the consumers.  
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In terms of the traditional media, the statements of the pharmaceutical companies 
signaled two different views. On the one hand, Company B mentioned TV, radio and 
magazines as their most important marketing channels for self-care medicines. 
Though Company A’s interviewee also mentioned these as important channels, he 
stated that they are quickly moving from traditional media to even social media. 
However, Company A’s interviewee also recognized the importance of the target 
market:  
“It depends on the product whether traditional media is more important; if seniors are the 
target group, perhaps TV and radio are better.” 
What was emphasized by all the interviewees of the pharmaceutical companies is the 
fast emergence of digital marketing in the medical industry. As examples of digital 
marketing they gave the video-sharing site Youtube, online-TV, the use of cookies, 
social media - such as Facebook-pages for some products - and online-banners. The 
fast growth of digitality shows in this quote from Company A’s interview:  
”10 years ago it was mostly banners and websites; over the last 5 years social media has 
had a breakthrough” 
However, there was a difference in the emphasis of digital marketing for the different 
pharmaceutical companies. Company A clearly stated that it uses more resources on 
digital marketing due to the ease of targeting and measuring as opposed to the 
traditional media. On the other hand, Company B stated the following about digital 
marketing:  
“Time is not right for completely moving to digital marketing since it is the certain group of 
people of the same age group who go to the pharmacies.” 
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5. DISCUSSION 
 
This section summarizes the key findings of the empirical research and analyzes them 
in terms of the existing literature which was discussed in the literature review. The goal 
of this is to provide answers for the research questions underlying this research. 
Therefore, this section aims to clarify what are the changes that have taken place in 
the Finnish market over the last 10-15 years and what marketing strategies are at use 
in the industry. Ultimately this section will discuss how the companies have changed 
their marketing strategies due to these changes. The themes occurred in the literature 
review will be touched upon in the same order as they were first presented in the 
literature review: first the industry changes will be analyzed and then then the 
marketing strategies.   
 
5.1. Changes in the industry 
 
The existence of industry changes in the Finnish market became evident in the 
interviews. The next paragraph will further specify which changes of the ones stated in 
the literature review were also recognized in the interviews.   
 
5.1.1. Decline in discovery, approval and marketing of new chemical entities 
 
Firstly, the literature states that it is crucial for the industry to constantly engage in R&D 
activities and new innovations to remain profitable. This was also recognized by the 
interviewees as both of the interviewed pharmaceutical companies named creating 
new innovations as their primary operations.  
However, the decline in discovering NCEs could not be seen in the interviews. On the 
contrary, all the interviewees seemed to think that the last years had been rather 
productive in terms of new drug development. The impact of the high failure rate in 
creating new medicines or the increased scrutiny was not noted by the companies. 
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The interviewees did mention the increased industry regulation but – unlike in the 
literature – did not link any decline in new product development to it.  
 
5.1.2. Market entry of generic drugs 
 
Similarly to the findings in the existing literature, all the interviewees recognized the 
fast and wide market entry of the generic drugs. They also notified the dramatic 
decrease in overall pricing due to this.  
The reasons that the previous literature presented for the market entry of the generic 
drugs were partly mentioned by the interviewees. The expiration of some old 
medecines’ patents came up in the interviews as one of the reasons for the generic 
drugs’ entrance. However, the interviewees did not seem to regard this development 
to be as dramatic as the literature presents; once a patent expired they stated that they 
strive to develop their own alternative to offer. In addition, the economic downturn was 
not mentioned as a reason for the generic entry. Rather the medical companies 
seemed to regard this recent development as the natural consequence of the 
regulatory environment which has become stricter. 
Overall, the interviewees seemed to regard the generic entry as a natural development 
that did not make a significant threat to their business. This differs from the view of the 
previous literature as it suggests that the generic entrance makes a big threat to the 
companies’ business. One reason for this might be what Lukkari and Parvinen (2008) 
present: in the Finnish market doctors are reluctant to change their prescribing habits 
which protects the branded products. In addition, what emerged from the interviews is 
that also the pharmacies tend to maintain the same companies in their product choice. 
Therefore, it can be stated that the Finnish market has some attributes that protect the 
status quo of the pharmaceutical industry. Though it is noteworthy that the interviewed 
drug companies were big companies with long traditions and stable customer 
relationships which means that they might not feel as threatened by new market 
entries. Similarly, the interviewed pharmacist was from a fairly small pharmacy with 
limited storage space which might affect the ability to accept new products.  
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5.1.3.  Regulatory changes 
 
In the literature review Finnish market was described as the typical European market 
with tight regulation. This was very much seen in the interviews as all the interviewees 
described the industry as very regulated. Moreover, it was stated in the literature that 
this makes it crucial for the companies operating in the market to maintain relationships 
with the different institutions and practitioners in the industry. The interviewees also 
agreed to this as they stated that it is very important for them to maintain relationships 
to different operators in the field.  
The increased regulation in the market was recognized by the interviewees. From the 
two main aspects of the increased regulation environment – the regulations brought by 
the EU and the reference price system – especially the reference price system was 
mentioned. One interviewee even described its impact as “dramatic”. On the other 
hand, the effects of the EU were minor if not inexistent according to the pharmaceutical 
companies. The effect of harmonizing legislation and the centralized markets brought 
by the EU were mentioned by one interviewee but the impact of them was considered 
small in Finland. Thus, the industry in Finland seems to be affected more by its inner 
regulative functions instead of the international and European regulation.  
 
5.1.4. The emerging markets  
 
The main point that arose from the interviews here was that the local managers of the 
international companies were fairly unaware of the changes in the manufacturing 
locations of their products. The company that did name some of their manufacturing 
locations mentioned some traditionally developed countries; USA and Sweden. Europe 
was also mentioned as a broad area but no specific locations. Thus, the E7 countries 
presented by the literature were not mentioned as emerging markets. The pharmacist 
mentioned India as one of the current manufacturing locations for many drugs but did 
not specify any companies or products. 
It should be taken into account here that the interviewees were reluctant to specify the 
manufacturing locations of their products. As a reason for this might be the genuine 
unawareness from the interviewees’ side. However, one interviewee only mentioned 
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the domestic manufacturing locations but refused to name any locations abroad. This 
implies that the companies might have inner policies restricting the sharing of this type 
of information externally. 
 
5.2. Marketing and sales in the industry  
 
The discussion will now move on to pharmaceutical marketing. It will present the 
current marketing practices used by the industry in Finland, comparing them to the 
marketing practices found in the previous literature and providing an analysis on the 
changes that have occurred in these practices within the last decade. The discussion 
is divided so that it will start with prescription-medicines and move on to self-care 
medicines.  
The literature stated that the prescription-medicines are the focus-point of companies 
conducting pharmaceutical marketing since they comprise the bulk of their sales. The 
empirical research failed to confirm this as the interviewed companies were reluctant 
to clarify their monetary importance – instead they stressed on their importance image-
wise.  
 
5.2.1. Prescription-Only medicines 
 
The theme that arose both from the literature and in the interviews, was the strict 
regulation that prohibits the companies from marketing prescription-medicines to the 
consumers. Also, what could be recognized from the interviews – though not directly – 
was that the means of social psychology, both financial and non-financial, were widely 
in use by the pharmaceutical companies. The foundation for current pharmaceutical 
marketing in Finland seems to be laid by the strict regulation which has led to 
companies increasingly borrowing practices from the field of social psychology. 
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5.2.1.1. Financial ways 
 
In terms of financial ways of marketing prescription medicines to the practitioners, gifts, 
education grants and sponsored research were mentioned in the literature review. Of 
these three, two were mentioned in the interviews. Here the industry changes were 
recognized the most by the interviewees. The interviews showed that the regulation 
has become notably stricter within the last decade; this prohibits the pharmaceutical 
companies from giving various gifts to pharmacists and doctors as they might have 
used to. The results showed that they are no longer allowed to even leave a pen with 
the product’s name to the doctor’s or the pharmacist’s. However, the interviews 
showed that it is normal for the pharmaceutical representatives to bring with them 
something to eat or something minor; the ground rule being that the inclusion of  brand 
names is not allowed. Though these may not seem like enormous gifts, they are 
enough to trigger reciprocity norms in the receivers – the doctors and pharmacists, that 
is. These reciprocity norms recognized by Sah and Fugh-Berman (2013) in the 
previous literature assure that the receivers might subconsciously feel that they “owe” 
something to the pharmaceutical companies. As stated by Blumenthal (2004), the size 
of the gift is insignificant when it comes to forming this type of reciprocal relationship.  
Also, providing different type of education was mentioned as an important channel for 
marketing the prescription medicines. The industry changes were apparent also here. 
The interviews showed that it is increasingly important to provide quality education that 
is experienced as neutral; this is the only way to get doctors and pharmacists to attend 
the education. In addition, the possibility for virtual training was named as one of the 
new possibilities brought by the advanced technology. Finally, providing education for 
the practitioners might also form reciprocity among them. The interviews showed that 
education provided by the pharmaceutical companies is often the only channel that 
provides free education for the doctors and pharmacists. Thus, it might also be 
considered as a type of gift. It is also a chance to remind the practitioners of the brand 
names. Though here it should be noted that the above-mentioned quality of education 
is indeed of high importance – as stated in the results, a completely commercialized 
educational event is no longer possible these days in the sense that it could not attract 
participants.  
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Finally, sponsored research was named as one financial way of marketing prescription 
medicines. This did not arise in the research as both pharmaceutical companies stated 
that sponsoring is not a part of their company policies.  
 
5.212. Non-financial ways 
 
When it comes to the non-financial ways of marketing prescription-medicines, the 
results show that the principles of persuasion presented in the literature are at use in 
the Finnish market. The keys in these principles are commitment, consistency, social 
proof, liking and authority in marketing. More specifically, the research showed that the 
use of representatives is the primary channel for conducting these means.  
Firstly, the results show that liking and social proof lay the foundation for the use of 
representatives in pharmaceutical marketing. Both the receiving and conducting end 
of the marketing prefer the same representatives visiting the same people at a regular 
basis. This enables forming a personal relationship between the representative and 
the practitioner. The importance of liking the representative even extends so far that 
the ability for the company to represent their products at all might be dependent on it. 
This is due to the receiving ends’ power of declining the representatives they do not 
wish to meet. The principles of consistency and commitment also arose in the research 
in the sense that the companies send representatives to visit the same people at a 
regular basis. This confirms the creation of a personal relationship. Therefore, the 
assumption presented in the literature of companies deliberately engaging in active 
networking with the practitioners is also accurate for current Finnish market.  
Moreover, the research showed that that the doctors and pharmacists mainly get 
information on new drugs from the pharmaceutical companies. This supports the 
notion of success for non-financial commitment that was presented in the literature. 
According to this notion, the key for success is that people tend to anchor on initial 
information. Thus, it is important for the pharmaceutical companies to be the first ones 
to share information on new innovations. This also explains the companies’ emphasis 
on creating new innovations – it is crucial to ensure the successful commitment of the 
doctors and pharmacists. In addition, the fact that people believe messages delivered 
with confidence was named as one of the key factors for the successful non-financial 
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commitment. Here the importance of providing quality education with proper speakers 
is relevant. This was also highlighted by the interviewees.  
 
5.22. Self-care medicines 
 
The literature presented two main themes in marketing when it comes to self-care 
medicines. These were personal selling and online marketing. Both were also 
mentioned by the interviewees. Also, the regulation that dictates the terms for the 
marketing of self-care medicines was – again – brought up in the interviews. 
Firstly, in terms of direct-to-consumer-advertising, the interviewees named both 
traditional and the new channels of digital marketing as important channels. The 
companies are increasingly striving to find better ways for targeted marketing. The 
literature addressed the issue of targeted marketing as women were targeted twice as 
much as men in advertising. The interviewees also confirmed this as it was stated that 
they try to choose magazines read by women since they are most often the ones 
buying medicines for the whole family.  
Moreover, the research showed the decreasing importance of the traditional media as 
marketing channels. However, this development was not as straight forward as one 
might expect; the companies also stated that traditional media remains important as 
the elderly are not yet fluid in using the internet. Being an important customer group 
for the pharmaceutical companies, they should be considered.  
Finally, the research showed that the challenge of applying the strict regulation for 
marketing medicines hinders the transformation for completely digital marketing. The 
law states that certain information must be present in an advertisement about drugs. 
As stated by the interviewees and the literature, this might be challenging in an online 
environment. It can be said, interestingly, that the trend of increasing industry 
regulation slows down the transformation to the digital era in terms of pharmaceutical 
marketing. The global discussions about increasing amount of online pharmacies that 
were presented in the literature do not concern the Finnish market as drugs are only 
sold in pharmacies.  
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6. CONCLUSIONS 
 
This section will conclude the thesis. First the main findings of the study will be 
presented. This will be followed by discussion on the implications this thesis has for 
international business. Finally, the section will end by presenting suggestions for 
further research and then the limitations of this study.  
 
6.1. Main Findings 
 
The research questions of the study were: (1) what changes have been seen in the 
Finnish market over the last 10-15 years, (2) what are the main marketing techniques 
used by the pharmaceutical companies in the Finnish market and (3) have the 
pharmaceutical companies changed their marketing practices or adopted new ones 
due to industry changes.  
To address the first question, as stated in the findings and discussion sections, some 
of the industry changes recognized in the previous literature were also apparent in the 
Finnish market. More specifically, the biggest industry changes recognized by the 
companies were the changing  regulatory environment and the market entry of the 
generic drugs. These seemed to carry rather a causal cause-effect relationship in the 
interviewees’ minds; the market entry of the generic drugs was seen as a natural cause 
from the regulatory changes (the generic substitution and the reference price system). 
The declining amount of the NCEs was not addressed by the companies as they rather 
noted an increase in the amount of new product launches over the last years. Similarly, 
the emergence of the new markets was not addressed. Though here it should be noted 
that the interviewees were not able to comment on the changes in the production 
locations due to lack of knowledge or company policies.  
Regarding the marketing techniques used by the pharma companies, the study 
showed the following. The most important marketing channels for prescription 
medicines were quite different from the main marketing channels for self-care 
medicines. The companies named representatives as the most important marketing 
channel for prescription medicines. For self-care medicines this was the different mass 
42 
 
media. It varied according to the company which was considered more important – the 
traditional media or the digital marketing and social media. 
Finally, the study showed that the industry change which had most affected the 
marketing strategies of the companies was the increasing regulation. Due to this, the 
companies have altered their use of representatives in the prescription side – for 
example banning the use of gifts – which has led to increased emphasis on maintaining 
and creating relationships to the doctors and pharmacists. In addition, the rapid 
increase of digital marketing and the possibilities brought by this, such as more specific 
targeting, was the change that had the most effect on the marketing strategies. Digital 
marketing is rapidly increasing in importance alongside the traditional mass media 
marketing. However, this change is hindered by the wide target audience for 
medicines, the elderly people, who mostly have not adopted the internet and social 
media in their daily usage.  
 
6.2. Implications for International Business 
 
The importance of this thesis to international business derives from the nature of the 
drug industry. The same multinational companies widely operate in the industry 
globally. Thus, the changes and marketing strategies that can be seen in the Finnish 
market also apply for the whole industry globally. Furthermore, Finland is a part of the 
EU and so its market is reflected by the European market and its ruling trends and 
regulatory policies.  
Moreover, the issue of pharmaceutical marketing remains important and should be 
continuously studied. The dilemma occurs from the differing interests of the entities 
operating in the field: on one hand, it should be ensured that the patients are provided 
with proper health care and treatments while, on the other hand, maintaining the 
business profitability for the pharmaceutical companies seeking returns for their 
business. This results in the ethical dilemma of pharmaceutical marketing; how much 
of a sales business can the pharmaceutical industry be while constantly taking the 
patients’ interest into consideration? Indeed, in terms of the well-being of individuals 
and more widely the society, the conflict of interest occurring in the interchange 
between the pharmaceutical companies remains an international issue. Though the 
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Finnish market has its own regulatory aspects and policies, this issue is the same 
which could be discovered from the interviews.   
 
6.3. Suggestions for Further Research 
 
The further research suggestions can be inspected in terms of the research objectives 
of this thesis. These objectives were (1) to find out which of the industry changes that 
were recognized by the previous literature were also recognized by the companies 
operating in the Finnish market, (2) to determine the main marketing methods for 
prescription and self-care medicines after the industry changes and (3) to explore if the 
industry changes have made the pharmaceutical companies in the Finnish market to 
change their marketing practices or adopt new ones. 
When it comes to the first objective, the research failed to find out whether there has 
occurred a change in the manufacturing locations of the companies’ medicines. Thus, 
this is an area that could be further researched. Also, the subject of the thesis is fairly 
wide to be conducted in such a narrow scope and time limit. The industry changes 
could be researched in a wider context, for example inside the EU, including multiple 
nations to the research. This would ensure a wider image of what is globally happening 
within the industry. 
In terms of the main marketing methods for medicines, this thesis does not include the 
end customer perspective of pharmaceutical marketing. As there always remains 
ethical issues when dealing with people’s health-care and well-being in pharmaceutical 
marketing, the customer experiences could be further researched. Also, the doctors’ 
prescription patterns could be further studied. Furthermore, the digitalization is an 
issue that was brought up several times over in the interviews. It would be useful to 
research the implications of the increasing digitalization to the pharmaceutical 
marketing.  
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6.4. Limitations 
 
This study has certain limitations which were mostly derived from the limited time 
available for conducting the research. Firstly, due to the time limitations the scope of 
the research is narrow and the amount of the empirical data is small. To thoroughly 
study the entire Finnish market, a larger number of interviews ought to be conducted 
from all the entity groups presented in this study – at minimum interviews from both 
the companies side and both entities who are the target of pharmaceutical marketing. 
This refers to the doctors and the pharmacists. This leads to the second limitation of 
the study. Due to the time limit, an interviewee with a doctor could not be included. 
This would have ensured a broader perspective of the experiences of the receivers’ 
experiences. Especially data concerning the marketing of prescription medicines is in 
this study mainly gathered from the companies conducting the marketing.  
The industry changes are alone a wide issue to be researched. Within the time limit it 
proved to be rather challenging to find interviewees who could answer to all the 
questions regarding the industry changes but would also have thorough knowledge on 
the current marketing practices of the companies. Therefore, some questions of this 
section remained unanswered as the interviewees simply did not have the knowledge 
or had not been in the company long enough to respond.  
Finally, using interviews as the research method had some issues. The pharmaceutical 
companies insisted on previewing the interview questions beforehand. This was not 
the situation with the pharmacists. This puts the interviewees in a different situation in 
answering the questions. In addition, using interviews always contains the danger of 
losing the interviewee’s initial message. Since the interviewees were conducted in 
Finnish and translated to English for this study, there remains a translation issue. Some 
ideas may be lost in the translation process. 
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APPENDICES 
 
Appendix 1: The question plan for the companies 
 
Background:  
 What are your main products?  
 Are your operations based in Finland or abroad?  
 How many people do you employ? How big is your market share?  
 How big budget do you have for marketing drugs?  
Changes:  
Decline in discovery, approval and marketing of new chemical entities 
 Approximately how many new product launches does your company make per 
year?  
 Has there been an increase/decrease in this amount in the past decade?  
The generic drugs entering the market 
 Do your products include more brand or generic drugs?  
 Which ones do you consider to be more important for your business?  
 Has the generic entrance had an impact on your products prices? 
 Do you consider the generic entrance a big threat?  
Changing regulation  
 Describe the impact of the reference price system and the generic substitution 
program to your products? 
 How has the membership of the EU affected your company?   
 The emerging new markets 
 Where do you manufacture your products?   
 What changes have there been in your manufacturing countries in the past 
decade? 
Marketing:  
 On which one do you think you company puts more emphasis, the marketing of 
prescription medicine or self-care? 
 How do you measure the success of your marketing? 
Prescription-medicine: 
 What is your company’s most important prescription product? 
 What do you consider to be your company’s main marketing channels for 
prescription medicine? 
-Non-financial ways (building networks to companies)  
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 How often do you have campaigns in collaboration with the pharmacists?  
 Do you regularly send representatives to visit pharmacists/doctors? 
 Do the same representatives visit the same targets year after year?  
 Do you have co-operation with pharmaceutical chains? 
 How would you describe the importance of maintaining relationships to 
practitioners to your company?  
-Financial ways (gifts, sponsored vacations)  
 Do you offer training for the practitioners?  
 Does your company sponsor different medical events? What for example?  
 Do your representors have hand-outs with them for their visits or also something 
else? What?  
Self-care medicine (OTC):  
 What are your company’s most important OTC medicines?  
 What do you consider to be your company’s main marketing channels for OTC 
drugs?  
 Do you use online marketing? What are your main online marketing channels? 
 Describe the marketing campaigns you have had in the past years? (Influential, 
emotional?) 
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